Literature DB >> 15585633

Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.

Maria Valeria Corrias1, Lawrence B Faulkner, Angela Pistorio, Cristina Rosanda, Francesco Callea, Maria Serena Lo Piccolo, Paola Scaruffi, Cinzia Marchi, Laura Lacitignola, Marzia Occhino, Claudio Gambini, Gian Paolo Tonini, Riccardo Haupt, Bruno De Bernardi, Vito Pistoia, Alberto Garaventa.   

Abstract

PURPOSE: Detection of metastatic tumor cells in bone marrow (BM) and peripheral blood (PB) of children with neuroblastoma is crucial for prognosis and planning of therapy. Aims of this large descriptive repeated survey were to evaluate the diagnostic accuracy of different techniques in diagnostic samples obtained at several disease course time points and to correlate positive results with patient clinical features and outcome. EXPERIMENTAL
DESIGN: BM aspirates, trephine biopsies, PB, and peripheral blood stem cell (PBSC) samples from Italian children with neuroblastoma were analyzed by morphological and histologic techniques, as well as by immunocytochemistry (IC) for disialoganglioside GD(2) and reverse transcription-PCRs (RT-PCRs) for tyrosine hydroxylase (TH) and pgp9.5 genes. The diagnostic odd ratio (DOR) was used to measure the accuracy of the different techniques.
RESULTS: A total of 2,247 evaluations were done on 561 BM, 265 PB, and 69 PBSC samples from 247 patients. IC showed the best accuracy. Whereas TH RT-PCR accuracy was satisfactory, that of pgp9.5 was very low. Positive results obtained by IC in BM and PB samples at diagnosis from stage 1, 2, and 3 patients correlated with unfavourable outcome. No correlation was found between positive results obtained by IC or TH RT-PCR in BM, PB, and PBSC samples from stage 4 patients and their outcome.
CONCLUSIONS: Because of its elevated diagnostic accuracy, IC may represent a useful adjunct to conventional morphological techniques, especially in view of its potential prognostic role in patients with localized disease. Longitudinal multicenter studies are warranted to definitely establish the clinical usefulness of TH RT-PCR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585633     DOI: 10.1158/1078-0432.CCR-04-0815

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.

Authors:  Yania Yáñez; David Hervás; Elena Grau; Silvestre Oltra; Gema Pérez; Sarai Palanca; Mar Bermúdez; Catalina Márquez; Adela Cañete; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-24       Impact factor: 4.553

2.  Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.

Authors:  Yania Yáñez; Elena Grau; Silvestre Oltra; Adela Cañete; Francisco Martínez; Carmen Orellana; Rosa Noguera; Sarai Palanca; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2011-06-25       Impact factor: 4.553

3.  Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.

Authors:  Rachel A Egler; Susan M Burlingame; Jed G Nuchtern; Heidi V Russell
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

4.  Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease.

Authors:  Morris Kletzel; Pauline M Chou; Marie Olszewski; Alfred W Rademaker; Sana Khan
Journal:  Transl Pediatr       Date:  2015-07

Review 5.  Opportunities and challenges of circulating biomarkers in neuroblastoma.

Authors:  Ricky M Trigg; Jacqui A Shaw; Suzanne D Turner
Journal:  Open Biol       Date:  2019-05-31       Impact factor: 6.411

6.  Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma.

Authors:  Neha Jain; Shaista Sattar; Sarah Inglott; Susan Burchill; Jonathan Fisher; Andreea-Madalina Serban; Rebecca Thomas; Chris Connor; Niharendu Ghara; Tanzina Chowdhury; Catriona Duncan; Giuseppe Barone; John Anderson
Journal:  F1000Res       Date:  2021-09-21

7.  Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.

Authors:  M V Corrias; S Parodi; R Haupt; L Lacitignola; F Negri; A R Sementa; D Dau; F Scuderi; B Carlini; M Bianchi; F Casale; L Faulkner; A Garaventa
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

8.  The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.

Authors:  Yuting Gu; Fan Lv; Mingxing Xue; Kai Chen; Cheng Cheng; Xinyuan Ding; Min Jin; Guofeng Xu; Yanyun Zhang; Zhixiang Wu; Leizhen Zheng; Yeming Wu
Journal:  J Exp Clin Cancer Res       Date:  2018-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.